A promising study published in The New England Journal of Medicine showed that semaglutide, the compound in Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic kidney disease. The findings of this major clinical trial could transform how doctors treat people with chronic kidney disease, a disease which affects millions of adults in the United States alone.
ITHS Co-PI Katherine R. Tuttle, M.D., is one of the lead authors of the study, and she told the New York Times, “Those of us who really care about kidney patients spent our whole careers wanting something better, and this is as good as it gets.”
The study included 3,533 patients who were randomly assigned to receive either a weekly dose of semaglutide or a placebo, with a median follow-up period of 3.4 years. The results showed a significant reduction in the risk of major kidney events for the semaglutide group compared to the placebo group…
Read the full article here.
